Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
Cantor Fitzgerald
Moodys
AstraZeneca
McKesson
Healthtrust
Chubb
Cipla

Generated: August 20, 2018

DrugPatentWatch Database Preview

LUSEDRA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Lusedra, and when can generic versions of Lusedra launch?

Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-four patent family members in twenty-five countries.

The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.

Summary for LUSEDRA
Drug patent expirations by year for LUSEDRA
Generic Entry Opportunity Date for LUSEDRA
Generic Entry Date for LUSEDRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for LUSEDRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Premature patent expiration for: LUSEDRA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Sign Up LUSEDRA ➤ Sign Up

Non-Orange Book US Patents for LUSEDRA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,451,776 Water soluble prodrugs of hindered alcohols ➤ Sign Up
7,244,718 Water soluble prodrugs of hindered alcohols ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Daiichi Sankyo
Baxter
Mallinckrodt
Dow
Cantor Fitzgerald
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.